Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.[1]
- Market Cap ₹ 50.8 Cr.
- Current Price ₹ 95.0
- High / Low ₹ 268 / 83.1
- Stock P/E 7.11
- Book Value ₹ 75.7
- Dividend Yield 0.00 %
- ROCE 26.2 %
- ROE 21.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 18 | 62 | 103 | |
| 16 | 53 | 92 | |
| Operating Profit | 2 | 9 | 11 |
| OPM % | 13% | 14% | 11% |
| 0 | 0 | 0 | |
| Interest | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 2 | 9 | 10 |
| Tax % | 28% | 27% | 28% |
| 2 | 6 | 7 | |
| EPS in Rs | 3.24 | 12.74 | 13.36 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -63% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 5 | 5 | 5 |
| Reserves | 13 | 23 | 35 |
| 2 | 3 | 13 | |
| 1 | 5 | 8 | |
| Total Liabilities | 21 | 36 | 61 |
| 0 | 2 | 2 | |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| 20 | 33 | 59 | |
| Total Assets | 21 | 36 | 61 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -4 | 1 | -13 | |
| -1 | -2 | -0 | |
| 13 | 3 | 5 | |
| Net Cash Flow | 9 | 2 | -8 |
| Free Cash Flow | -4 | -0 | -14 |
| CFO/OP | -144% | 21% | -110% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 66 | 86 | 101 |
| Inventory Days | 63 | ||
| Days Payable | 10 | ||
| Cash Conversion Cycle | 66 | 86 | 153 |
| Working Capital Days | 187 | 86 | 126 |
| ROCE % | 35% | 26% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Geographic Presence (States/UTs) count ・Standalone data |
|
|
| Permanent Employees count ・Standalone data |
||
| New Products Launched count ・Standalone data |
||
| Satisfied Customers count ・Standalone data |
||
| Total Product Portfolio count ・Standalone data |
||
| US FDA Approvals Obtained count ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
- Book Closure For AGM For FY2025-26
- Reg. 34 (1) Annual Report.
- Notice Of 3Rd Annual General Meeting Of Royal Sense Limited-FY2025-26
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 3Rd September, 2026
- Board recommended Rishabh Arora’s MD reappointment for 3 years and fixed AGM on 28 September 2026.
-
Announcement Under Regulation 30 Of SEBI(LODR)Regulations, 2015 - Clarification On Price Movement
- Company replied to BSE price movement query, citing no undisclosed price-sensitive information.
Business Overview:[1][2]
RSL deals in Advanced medical devices, pharmaceuticals, diagnostics, and offers surgical solutions. It provides hospitals, laboratories, clinics, and institutions
with products like surgical accessories, instruments, equipment, consumables,
reagents, diagnostic kits, and disposable
medical supplies